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The aim of this prospective, uncontrolled clinical study was to evaluate the tolerability and the efficacy of levetiracetam as
add-on treatment in 78 adults and 44 children with intractable epilepsy. The patients’ seizure frequency in the 8 weeks baseline
period was compared to their seizure frequency after a mean follow-up of 8 months of treatment.
A greater than 50% reduction in seizure frequency was achieved in 31 adults (40%) and 9 children (20%), of whom 7 adults (9%)
and 3 children (7%) became seizure free. Most often levetiracetam was well tolerated, somnolence being the most frequently
reported side effect (18% in adults and 7% in children). However, in 14 adults (18%) and 19 children (43%) levetiracetam
was associated with an increase (>25%) in seizure frequency. Such a paradoxical effect, including the development of status
epilepticus in three adults and four children, appeared most often in mentally retarded patients during the first 2 months of
treatment, and on relatively high doses. Two children developed status epilepticus after 5 and 7 months, respectively.
In conclusion, levetiracetam is usually well tolerated as add-on treatment in patients with difficult-to-treat partial onset seizures.
By using a lower initial dose and a slower dose escalation than recommended by the manufacturer, a paradoxical effect may
perhaps be avoided. In children, doses >20 mg kg−1 per day should be introduced with caution.
© 2002 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved.
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INTRODUCTION
Levetiracetam is a new antiepileptic drug (AED)
with a unique preclinical profile, favourable pharma-
cokinetic properties, a wide therapeutic index and
a high margin of safety. The drug may also have
an antiepileptogenic effect, as it seems to prevent
the development of amygdala kindling in rodents1.
Levetiracetam seems to have a selective stereo-specific
binding site in the brain, but its exact mode of action
is still unknown2.
In clinical studies levetiracetam, given in doses of
500, 1000 and 1500 mg, b.i.d., has proven effective
as add-on treatment in adult patients with intractable
partial onset seizures with and without secondary
generalisation3. Lately, the drug has also been shown
to have effect on generalised seizures4.
We report the results of an uncontrolled, prospective
clinical study performed at our tertial referral center.
The aim of the study was to evaluate the tolerability
and the efficacy of levetiracetam as add-on treatment
in both adults and children with difficult-to-treat
epilepsy.
PATIENTS AND METHODS
Since September 2000, 78 adults and 44 children
with refractory epilepsy have received levetiracetam
as add-on treatment at our center. The patient char-
acteristics are shown in Table 1 (adults) and Table 2
(children). Total 13 (17%) of the adults and 39
(89%) of the children were mentally retarded. To
be included in the study the patients had to fulfil
the following criteria: a verified diagnosis of gener-
alised or localisation-related epilepsy, at least four
seizures in the 8-week baseline period, and tak-
ing at least one AED. Patients with a progressive
neurological disorder or nonepileptic seizures were
excluded.
After the 8-week baseline period the patients started
treatment with levetiracetam. The dose escalation for
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Table 1: Baseline demographic and clinical characteristics of the adults (n = 78).
Male/female 35/43
Mean age, (y; range) 33.2 (16–55)
Mean duration of epilepsy, (y; range) 20.2 (2–42)
Etiology of epilepsy Symptomatic, 23 patients
Cryptogenic/idiopathic, 55 patients
Type of epilepsy Localisation-related, 66 patients
Generalised, 12 patients
Mild mental retardation 13 patients
Seizure frequency >1 seizure per day, 18 patients
>1 seizure per week, 29 patients
>2 seizure per month, 31 patients
Mean number of AEDs tried (range) 8.3 (2–14)
Mean number of AEDs used in the baseline period (range) 1.9 (1–4)
Concomitant AEDs CBZ, 32 patients
VPA, 24 patients
LTG, 22 patients
OCBZ, 19 patients
TPM, 15 patients
Tried epilepsy surgery 18 patients
Tried VNS 14 patients
AED, antiepileptic drug; CBZ, carbamazepine; VPA, valproate; LTG, lamotrigine; OCBZ, oxcarbazepine; TPM, topiramate; VNS, vagal
nerve stimulation.
Table 2: Baseline demographic and clinical characteristics of the children (n = 44).
Male/female 25/19
Mean age (y; range) 10.0 (3–17)
Mean age at onset of epilepsy (y; range) 2.9 (0–10)
Etiology of epilepsy Symptomatic, 10 patients
Cryptogenic, 34 patients
Type of epilepsy Localisation-related, 21 patients
Multifocal/generalised, 23 patients
Mild mental retardation 17 patients
Severe mental retardation 22 patients
Seizure frequency ≥1 seizure per day, 38 patients
Weekly seizures, 6 patients
Mean number of AEDs tried (range) 8.5 (5–12)
Mean number of AEDs used in the baseline period (range) 1.4 (1–4)
Concomitant AEDs LTG 25 patients
VPA 10 patients
TPM 9 patients
CZP 7 patients
OCBZ 5 patients
NZP 4 patients
Tried ketogen diet 5 patients
Tried VNS 5 patients
Tried epilepsy surgery 2 patients
AED, antiepileptic drug; LTG, lamotrigine; VPA, valproate; TPM, topiramate; CZP, klonazepam; OCBZ, oxcarbazepine; NZP,
nitrazepam; VNS, vagal nerve stimulation.
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adults was 250 mg b.i.d. in the first week, 500 mg
b.i.d. in the second week, and 1000 mg b.i.d. in the
third week. In some patients, depending on the clin-
ical situation, the levetiracetam dose was increased
to a maximum dose of 3500 mg daily in the fourth
week.
The mean number of AEDs in the baseline period
was 1.9 (1–4) in the adults, and 1.4 (1–4) in the
children. Mean levetiracetam dose in the adults was
2360 mg (500–3500 mg); in the children the major-
ity received approximately 20 mg kg−1 (10–40). The
children started with a dose of 5 mg kg−1 b.i.d., in-
creasing the dose every fortnight by 5 mg kg−1 b.i.d.
to a maximum daily dose of 40 mg kg−1.
The co-medication most frequently used was carba-
mazepine (CBZ) and valproate (VPA) in the adults,
and lamotrigine (LTG) and VPA in the children
(Tables 1 and 2). The co-medication was kept constant
throughout the study in both adults and children.
The adult patients were monitored at our outpa-
tient clinic with 4–6 weeks intervals. At each visit a
drug fasting blood sample was drawn for drug anal-
ysis of the co-medication, and the seizures (seizure
types, frequency, duration, and severity) and side
effects were evaluated. The children were moni-
tored by telephone interviews every fortnight, and in
special occasions by consultation at the outpatient
clinic.
After a mean follow-up period of 8 months the
patients’ seizure frequency was compared to their
baseline condition. Each patient acted as his/her own
control.
RESULTS
Adults
After a mean follow-up period of 8 months (3–17
months) 31 patients (40%) were responders, i.e. they
achieved >50% reduction in seizure frequency. Seven
of these patients (9%) became seizure free. Four-
teen patients (18%) experienced an increased seizure
frequency (defined as >25% increase compared to
the baseline period). Three of them developed sta-
tus epilepticus (one with convulsive, and two with
nonconvulsive status epilepticus), all within 4 weeks
after introduction of levetiracetam. Four patients de-
veloped a greater tendency for generalisation of their
partial seizures, i.e. they had more frequent secondary
generalised tonic–clonic seizures.
Twenty-eight patients (36%) reported side effects;
especially somnolence (14 patients, 18%) (Table 3).
Irritability and aggression (three patients, 4%) were
only seen in mentally retarded patients. Among the 50
patients without side effects 8 of them spontaneously
Table 3: Side effects of levetiracetam among the adults
(n = 78).
Number of Percentage
patients
Increased seizure frequency 14 18
Somnolence 14 18
Dizziness 5 5
Headache 4 6
Irritability 3 4
Slow cerebration 2 3
Sleep disturbance 1 1
Depression 1 1
Psychosis 1 1
Pruritus 1 1
reported that they felt better and more alert while tak-
ing levetiracetam.
After 8 months, 43 patients were still treated with
levetiracetam, i.e. a preliminary retention rate of 55%.
Increased seizure frequency (14 patients, 18%) and
lack of seizure-reducing effect (19 patients, 24%) were
the most common causes for drug withdrawal.
All responders had localisation-related epilepsy.
Otherwise, the responders did not differ from the
nonresponders with respect to age, gender, duration
of epilepsy, etiology of epilepsy, or seizure frequency.
There was a slight tendency towards a weaker effect
of the drug among those who were mentally retarded
compared to those who were not. Antiepileptic effect
was seen in all types of seizures, both partial and
generalised.
There were no significant changes in the serum con-
centrations of the concomitant AEDs.
Children
At the end of the follow-up period, on average 8
months (3–14 months), 9 of the 44 children (20%)
had >50% reduction in seizure frequency. Three
of these patients (7%) became seizure free. In 19
patients (43%) levetiracetam was associated with
an increased seizure frequency at a mean dose of
30 mg kg−1 (10–40 mg kg−1). The seizure aggrava-
tion appeared after an average treatment period of 7.7
weeks (3–12 weeks). Initially, half of these children
had a good response (>50% reduction in seizure fre-
quency), while the remaining children had no clinical
benefit during titration. Three children developed a
new seizure type, i.e. apnoeic attack (see Case 1).
During titration one child developed impending com-
plex partial status epilepticus and another patient
developed nonconvulsive status epilepticus. Two chil-
dren developed convulsive status epilepticus after 5
and 7 months on levetiracetam, respectively. None of
them had previously experienced status epilepticus
(see Case 2).
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Case 1. A 4-year-old boy with trisomi 10p and
Lennox Gastaut Syndrome initially had a good res-
ponse to levetiracetam with >50% decreased fre-
quency of tonic seizures. After the dose had been
titrated to 33 mg kg−1, he suddenly developed apnoeic
attacks every 30 minutes. He was admitted to hospital,
and levitiracetam was withdrawn. Forty-eight hours
later the apnoeic attacks disappeared, and his seizure
frequency returned to baseline level.
Case 2. A 10-year-old girl with cryptogenic par-
tial epilepsy had a baseline seizure frequency of 15
seizures per day (tonic and tonic–clonic seizures). On
a levetiracetam dose titrated from 10 to 30 mg kg−1
her seizure frequency was reduced to five to seven
seizures per day, but on 40 mg kg−1 the seizure fre-
quency increased to 20 seizures per day. The dose
was reduced to 15 mg kg−1 and kept constant during
the following 4 months. Her seizure frequency in
this period was five to seven seizures per day. Then
she suddenly developed tonic–clonic status epilepti-
cus. Levetiracetam was withdrawn. She is now being
treated with vagal nerve stimulation (VNS) and has
been seizure free for more than 6 months. We have no
other explanation to the development of status epilep-
ticus in this patient other than a possible relationship
to levetiracetam.
Effect of levetiracetam was seen both in partial
and generalised seizures, generalised tonic–clonic
seizures being the seizure type most often affected.
The most frequently reported side effects were som-
nolence, dizziness, and ataxia. ‘Forced normalisation’
with psychosis was seen in one patient (Table 4).
At the end of the follow-up period (mean 8 months)
levetiracetam had been withdrawn in 29 patients
(66%), mostly due to increased seizure frequency (19
patients, 43%) and lack of effect (10 patients, 23%).
In all patients in whom levetiracetam was associated
with an increased seizure frequency, withdrawal of
the drug led to a marked seizure reduction. At the
end of the follow-up period the retention rate of leve-
tiracetam in the children was 34%.
Table 4: Side effects of levetiracetam among the children
(n = 44).
Number of Percentage
patients
Somnolence 3 7
Dizziness 3 7
Ataxia 3 7
Behavioural problems 1 2
‘Forced
normalisation’ with
psychosis
1 2
DISCUSSION
The seizure-reducing effect of levetiracetam as add-
on therapy achieved in the adult patients was fairly
comparable to reports in previous studies3. In most
patients the drug seemed to be well tolerated, and
no clinically significant drug interactions were en-
countered. However, the relatively high proportion
of patients with a paradoxical effect of levetiracetam
(adults, 18%; children, 43%) has previously not been
reported.
The results from this study must be interpreted with
caution. As the patients are recruited from a referral
center, there is a selection bias against patients with
very difficult-to-treat epilepsy. The lack of a control
group is another limitation. On the other hand, we be-
lieve that the study conditions closely resemble every-
day clinical practice. Hence, the results are probably
representative for patients with intractable epilepsy.
In the last two decades there has been accumu-
lating evidence that several AEDs (phenytoin, CBZ,
vigabatrin, benzodiazepines, LTG, topiramate (TPM),
tiagabine) may induce worsening of epilepsy by ag-
gravating pre-existing seizures or/and triggering new
seizure types5, 6. However, much of the evidence for
this has been published in anecdotal form or is based
on a small number of patients. Clinicians often face
great difficulties in establishing a correct cause–effect
relationship between the introduction of an AED and
worsening of seizures. Ideally, it would be neces-
sary to show improvement after withdrawal of the
drug followed by renewed worsening secondary to
its re-introduction. Such a procedure would, however,
be unethical. The biological mechanisms involved
in this phenomenon are unknown. Sometimes in-
creased seizure frequency is triggered by an AED
overdosage, most frequently reported for phenytoin7.
Seizure aggravation has also been associated with dif-
ferent AEDs at nontoxic serum concentrations. It is
mounting evidence that these AEDs may provoke ag-
gravation purely by a pharmacodynamic mechanism;
whether this is due to inappropriate choice of the
AED, or to a paradoxical reaction is controversial8.
Seizure aggravation triggered by AEDs is proba-
bly more common in children than in adults, espe-
cially among mentally retarded children with ‘mixed
seizure disorders’8. AEDs with a defined mechanism
of action, particularly GABA-ergic drugs, are likely to
provoke generalised seizures. For example vigabatrin
may trigger myoclonic jerks and absences, and benzo-
diazepines may trigger tonic seizures in patients with
Lennox Gastaut Syndrome9, 10. Some possible expla-
nations for seizure aggravation are listed in Table 5.
We have no plausible explanation why an addition
of levetiracetam apparently caused a seizure aggrava-
tion in several patients in the present study. There was
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Table 5: Possible explanations for a paradoxical effect of
AEDs.
Toxic serum concentrations of the new drug
(‘paradoxical intoxication’)
Natural fluctuation of seizure frequency
Progressive brain lesion
Intercurrent illness or other seizure-precipitating factors
Drug-induced drowsiness
Low serum concentration of co-medication due to:
tapering off co-medication
pharmacokinetic interaction with the new drug
noncompliance
Development of tolerance
Adverse pharmacodynamic effect and/or interaction
Inappropriate drug for a specific epilepsy syndrome
Nonepileptic seizures
no evidence of drug interactions or of noncompliance.
Retrospectively, one may speculate if the dose escala-
tion was too fast or the target dose too high, at least
in some patients. Among the children we noticed that
some patients treated with high doses of levetiracetam,
>30 mg kg−1, experienced a ‘paradoxical intoxication’
i.e. an increased seizure frequency without other signs
of intoxication. The fact that the seizure frequency re-
turned to baseline levels after levetiracetam had been
withdrawn, argues against the assertion that the ob-
served seizure exacerbation was part of natural fluc-
tuations. Some of the children experienced increased
seizure frequency after several months of good seizure
control on a stable levetiracetam dosage. Withdrawal
of the drug led to a marked seizure reduction. The ex-
planation for this remains unknown.
The number of adult patients with generalised
epilepsies was too small to evaluate the efficacy of
levetiracetam in such epilepsies. Also the children
group was too small and too heterogeneous to esti-
mate the effect of levetiracetam in different epilepsy
syndromes.
Based on our preliminary clinical experience leve-
tiracetam seems to be a good alternative as an add-on
treatment in patients with partial onset seizures,
mostly due to good efficacy and no pharmacokinetic
interactions. We propose a lower initial dose and
a slower dose escalation than recommended by the
manufacturer; in adults 250 mg daily as an initial
dose, increasing the dose with 250 mg per week, and
in children 5 mg kg−1 as an initial dose, especially
in mentally retarded children, increasing the dose
with 5 mg kg−1 every second week. However, due
to the possible relationship between levetiracetam
doses above 30 mg kg−1 and a paradoxical effect
in children, doses above 20 mg kg−1 must be intro-
duced with caution. If increased seizure frequency
or apnoeic attacks occur, a gradual dose reduction or
withdrawal of the drug is recommended.
In an ongoing study we are investigating a possi-
ble relationship between clinical efficacy/paradoxical
effect and serum concentrations of levetiracetam, as
well as the influence of a slow dose escalation.
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